Inovio Pharmaceuticals (INO) has been beaten down lately with too much selling pressure. While the stock has lost 11.4% over ...

Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. INOVIO (NASDAQ ...

Shares of Inovio Pharmaceuticals Inc. INO advanced 1.90% to $1.61 Friday, on what proved to be an all-around positive trading ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Inovio Pharmaceuticals, Inc.’s INO share price has surged by 10.67%, which has investors questioning if this is right time to sell.

Good afternoon, ladies and gentlemen, and welcome to the INOVIO Pharmaceuticals fourth quarter 2024 financial results conference call. At this time, all lines are in listen-only mode. Following ...

CEO Jacqui Shea highlighted that Inovio remains committed to transforming into a commercial-stage company, with a primary focus on advancing INO-3107, a DNA medicine for recurrent respiratory ...